Total Payments
$858,182
2023 Payments
$51.81
Companies
28
Transactions
584
Medicare Patients
1,972
Medicare Billing
$499,321
Payment Breakdown by Category
Research$687,920 (80.2%)
Consulting$71,007 (8.3%)
Other$48,963 (5.7%)
Travel$32,634 (3.8%)
Food & Beverage$10,703 (1.2%)
Education$6,956 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $687,920 | 221 | 80.2% |
| Consulting Fee | $71,007 | 21 | 8.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,913 | 20 | 5.6% |
| Travel and Lodging | $32,634 | 98 | 3.8% |
| Food and Beverage | $10,703 | 214 | 1.2% |
| Education | $6,956 | 8 | 0.8% |
| Grant | $1,050 | 2 | 0.1% |
Payments by Type
Research
$687,920
221 transactions
General
$170,262
363 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $282,892 | 97 | $0 (2019) |
| Lupin Inc. | $224,313 | 10 | $0 (2018) |
| Ichnos Sciences Inc. | $143,620 | 27 | $0 (2022) |
| GlaxoSmithKline, LLC. | $60,901 | 106 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $34,517 | 73 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $21,058 | 59 | $0 (2021) |
| Circassia Pharmaceuticals Inc | $18,031 | 15 | $0 (2018) |
| Mylan Specialty L.P. | $17,477 | 22 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $12,748 | 35 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,375 | 7 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $51.81 | 1 | Blueprint Medicines Corporation ($51.81) |
| 2022 | $21,237 | 7 | Ichnos Sciences Inc. ($18,104) |
| 2021 | $15,102 | 5 | Ichnos Sciences Inc. ($10,518) |
| 2020 | $143,893 | 43 | Ichnos Sciences Inc. ($114,998) |
| 2019 | $84,446 | 146 | Glenmark Pharmaceuticals Inc. ($50,502) |
| 2018 | $347,073 | 237 | Lupin Inc. ($224,313) |
| 2017 | $246,379 | 145 | Glenmark Pharmaceuticals Inc. ($189,642) |
All Payment Transactions
584 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $51.81 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/08/2022 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Immunology and Neurology | ||||||
| 07/26/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $1,384.61 | General |
| 07/26/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $1,118.70 | General |
| 07/26/2022 | GlaxoSmithKline, LLC. | — | Grant | Cash or cash equivalent | $450.00 | General |
| 07/26/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $158.13 | General |
| 02/07/2022 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $17,766.83 | Research |
| Study: ISB830-204 | ||||||
| 02/03/2022 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $337.54 | Research |
| Study: ISB830-204 | ||||||
| 11/22/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/28/2021 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/28/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: RESPIRATORY | ||||||
| 06/28/2021 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $3,019.37 | Research |
| Study: GBR830-204 | ||||||
| 03/04/2021 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $7,498.67 | Research |
| Study: GBR830-204 | ||||||
| 12/09/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Respiratory | ||||||
| 12/03/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $9,530.53 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 11/11/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Respiratory | ||||||
| 10/20/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 10/06/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 08/20/2020 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $389.00 | General |
| Category: Respiratory | ||||||
| 08/12/2020 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Respiratory | ||||||
| 07/20/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $42,927.87 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 07/20/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $3,037.88 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 06/12/2020 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Respiratory | ||||||
| 06/02/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $7,968.16 | General |
| Category: RESPIRATORY | ||||||
| 06/01/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $24.75 | General |
| Category: Respiratory and Allergy | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $224,313 | 10 |
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $189,642 | 15 |
| GBR830-204 | Ichnos Sciences Inc. | $125,516 | 25 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $50,502 | 58 |
| ISB830-204 | Ichnos Sciences Inc. | $18,104 | 2 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $17,778 | 7 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $4,894 | 1 |
| NONE | Chiesi USA, Inc. | $2,694 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $1,976 | 16 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,617 | 9 |
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,502 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $1,350 | 13 |
| A Phase IIb, 24 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once daily via a dry powder inhaler, versus placebo, in participants with asthma | GlaxoSmithKline, LLC. | $1,293 | 7 |
| Randomised, Double Blind Sponsor Open , Placebo Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructiv | GlaxoSmithKline, LLC. | $1,256 | 4 |
| A Randomised PhIII study to assess the effect of 100 mg SC Mepolizumab in the nasal polyp score and symptoms in subjects with bilateral Nasal polyps NP and in current need of NP surgery | GlaxoSmithKline, LLC. | $1,234 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST | GlaxoSmithKline, LLC. | $1,156 | 5 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic O | SANOFI US SERVICES INC. | $998.79 | 11 |
| AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T | GlaxoSmithKline, LLC. | $992.02 | 7 |
| A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE BLIND, 3-ARM PARALLEL GROUP S | GlaxoSmithKline, LLC. | $735.75 | 7 |
| 201832 A Randomised, Double Blind, Double Dummy, Crossover Comparison of Fluticasone Furoate Vilanterol 100 25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects with Asthma and Exercise Induced Bronchoconst | GlaxoSmithKline, LLC. | $575.20 | 1 |
| A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $60.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 438 | 9,362 | $943,352 | $106,711 |
| 2022 | 8 | 514 | 11,755 | $1.2M | $128,834 |
| 2021 | 9 | 565 | 12,582 | $1.1M | $142,000 |
| 2020 | 7 | 455 | 11,669 | $853,570 | $121,777 |
Total Patients
1,972
Total Services
45,368
Medicare Billing
$499,321
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 109 | 6,102 | $604,098 | $69,189 | 11.5% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 167 | 1,845 | $182,655 | $13,604 | 7.4% |
| 95180 | Injection for rapid desensitization to allergen | Office | 2023 | 23 | 77 | $35,805 | $7,599 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 68 | $47,260 | $6,899 | 14.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $20,988 | $3,682 | 17.5% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 19 | 930 | $26,970 | $2,273 | 8.4% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 18 | 299 | $14,651 | $1,759 | 12.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 19 | $10,925 | $1,707 | 15.6% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 134 | 7,572 | $749,628 | $86,568 | 11.5% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 181 | 1,923 | $261,977 | $13,703 | 5.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 63 | 74 | $51,570 | $8,258 | 16.0% |
| 95180 | Injection for rapid desensitization to allergen | Office | 2022 | 19 | 56 | $26,406 | $5,716 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $30,822 | $5,458 | 17.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 30 | 1,591 | $46,139 | $4,104 | 8.9% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 28 | 478 | $23,422 | $2,602 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 28 | $15,614 | $2,425 | 15.5% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 160 | 8,740 | $752,020 | $102,837 | 13.7% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 212 | 1,537 | $213,643 | $12,153 | 5.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 68 | 79 | $49,623 | $9,116 | 18.4% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 29 | 1,618 | $40,450 | $4,692 | 11.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 28 | 28 | $24,352 | $4,580 | 18.8% |
| 95180 | Rapid desensitization procedure, each hour | Office | 2021 | 13 | 35 | $17,835 | $3,673 | 20.6% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 26 | 482 | $18,798 | $3,106 | 16.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 17 | 18 | $9,066 | $1,605 | 17.7% |
| 95115 | Injection of incremental dosages of allergen | Office | 2021 | 12 | 45 | $3,555 | $238.68 | 6.7% |
About Dr. Edward Kerwin, M.D
Dr. Edward Kerwin, M.D is a Allergy healthcare provider based in Medford, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568465847.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Kerwin, M.D has received a total of $858,182 in payments from pharmaceutical and medical device companies, with $51.81 received in 2023. These payments were reported across 584 transactions from 28 companies. The most common payment nature is "" ($687,920).
As a Medicare-enrolled provider, Kerwin has provided services to 1,972 Medicare beneficiaries, totaling 45,368 services with total Medicare billing of $499,321. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Medford, OR
- Active Since 05/31/2005
- Last Updated 07/10/2020
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1568465847
Products in Payments
- TIOTROPIUM (Drug) $224,313
- GBR830-204 (Drug) $114,998
- LONHALA MAGNAIR (Drug) $20,448
- UTIBRON (Drug) $14,317
- Yupelri (Drug) $13,771
- STIOLTO RESPIMAT (Drug) $9,783
- NUCALA (Biological) $9,107
- FASENRA (Drug) $7,828
- ANORO (Drug) $6,702
- BREZTRI AEROSPHERE (Drug) $6,027
- Wixela Inhub (Drug) $2,490
- MK-7264 (Drug) $2,378
- SAR440340 (Drug) $2,349
- DUPIXENT (Drug) $1,643
- QVAR (Drug) $1,631
- Xolair (Biological) $1,442
- BEVESPI AEROSPHERE (Drug) $1,347
- VERAMYST (Drug) $1,293
- PROAIR (Drug) $1,061
- TRELEGY ELLIPTA (Drug) $1,031
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.